

TARRYTOWN, N.Y., Oct. 3, 2013 /PRNewswire/ -- Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) announced today that Dr.

Daniel G. Teper

, Company Chairman and CEO, will be presenting at the 12th Annual

[BIO Investor Forum](#)

. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The presentation will take place on Wednesday, October 9, 2013

at

10:00 AM

local time at the Palace Hotel, Room Presidio in San Francisco, California

Dr. Teper will provide an update on development programs and 2014 milestones. The webcast of Dr. Teper's presentation will be accessible live and for the next 90 days at www.immunepharmaceuticals.com

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. (OTCQX and NASDAQ OMX Stockholm Exchange: IMNP) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company's lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn's disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company's growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors.

Immune is headquartered in Tarrytown, New York, with its primary research and development

facilities in Herzliya-Pituach, Israel.

For more information, visit Immune's website at www.immunepharmaceuticals.com .

ABOUT THE BIO INVESTOR FORUM The 12th Annual [BIO Investor Forum](#) is an international investor conference focused on private and emerging public biotech companies. Because our mission is to support industry-wide success, we present a broad and unbiased view of investment opportunities. In addition, the BIO Investor Forum draws business development executives from leading global pharmaceutical and established biotechnology companies.

SOURCE Immune Pharmaceuticals Inc.

RELATED LINKS <http://www.immunepharmaceuticals.com>